Literature DB >> 19960854

Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement.

Nina Avshovich1, Nina Boulman, Gleb Slobodin, Abdel-Rauf Zeina, Itzhak Rosner, Michael Rozenbaum.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19960854

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


× No keyword cloud information.
  3 in total

Review 1.  Non-infectious orbital vasculitides.

Authors:  B Perumal; E H Black; F Levin; J J Servat
Journal:  Eye (Lond)       Date:  2012-02-24       Impact factor: 3.775

2.  Rituximab for refractory granulomatous eye disease.

Authors:  Elyse E Lower; Robert P Baughman; Adam H Kaufman
Journal:  Clin Ophthalmol       Date:  2012-10-05

3.  Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

Authors:  Hans-Peter Tony; Gerd Burmester; Hendrik Schulze-Koops; Mathias Grunke; Joerg Henes; Ina Kötter; Judith Haas; Leonore Unger; Svjetlana Lovric; Marion Haubitz; Rebecca Fischer-Betz; Gamal Chehab; Andrea Rubbert-Roth; Christof Specker; Jutta Weinerth; Julia Holle; Ulf Müller-Ladner; Ramona König; Christoph Fiehn; Philip Burgwinkel; Klemens Budde; Helmut Sörensen; Michael Meurer; Martin Aringer; Bernd Kieseier; Cornelia Erfurt-Berge; Michael Sticherling; Roland Veelken; Ulf Ziemann; Frank Strutz; Praxis von Wussow; Florian M P Meier; Nico Hunzelmann; Enno Schmidt; Raoul Bergner; Andreas Schwarting; Rüdiger Eming; Michael Hertl; Rudolf Stadler; Michael Schwarz-Eywill; Siegfried Wassenberg; Martin Fleck; Claudia Metzler; Uwe Zettl; Jens Westphal; Stefan Heitmann; Anna L Herzog; Heinz Wiendl; Waltraud Jakob; Elvira Schmidt; Klaus Freivogel; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2011-05-13       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.